We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Combined jab as effective as separate shots in early stage tests
UK drugmaker steps up investment in long-acting medication to protect those exposed to the virus
FT research finds dangerously high bed occupancy levels and delays for A&E treatment
Cheaper valuations have finally drawn back cash-rich pharmaceutical makers
Point is developing radioligand molecules that can deliver targeted radiation to tumour cells
Drugmaker says settlements will avoid costly litigation but claims are ‘without merit’
Millions of us live with this debilitating condition. One sufferer describes taking matters into her own hands
Companies have yet to provide investors with convincing post-pandemic strategies
BMA asks for Acas to mediate, but ally of health secretary appears to pour cold water on reopening talks
Oxford university shot expected to deliver ‘sufficient’ supply for all at-risk infants
Katalin Karikó and Drew Weissman praised for role in ‘unprecedented rate of development’ of coronavirus jabs
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Economic and political fallout from war distracts governments from health threats
Recent warnings are the latest in a series of scares, but the industry says sugar substitutes remain a vital weapon against obesity and diabetes
Steve Barclay heightens tension ahead of party conference with attack on consultants earning £130,000 a year
Soaring sales for Novo Nordisk’s products mean market capitalisation now exceeds country’s GDP
Many doctors, nurses and other staff who enter professional training never join full-time workforce, Nuffield Trust finds
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
The latest findings build on experiments from over a century ago
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
Addressing this IP issue is crucial to ensuring pharmaceutical products are available in future emergencies
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
Figure rises to £18bn for a complete overhaul of system, according to Health Foundation study
Biobank deadlock is a symptom of the UK’s ailing innovation sector
If you can, save early as costs are rising - by more than a fifth in the past five years
UK Edition
